Alnylam price target raised to $125 from $82 at Leerink Leerink raised its price target for Alnylam shares to $125 citing the company's "impressive" partnership with Genzyme. The firm keeps an Outperform rating on the stock.
Alnylam transthyretin amyloidosis treatment designated for FDA orphan status Alnylam's revusiran was designated by the FDA for orphan drug status as a treatment of transthyretin amyloidosis. Reference Link
UBS to hold a conference Global Healthcare Conference is being held in New York on May 18-20 with webcasted company presentations to begin on May 19 at 8 am; not all company presentations may be webcasted. Webcast Link